Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lumito ABNGM:LUMITO +10.00%18 OCF Margin % is -8,630.77% as of Mar. 2026. GuruFocus rates NGM:LUMITO with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Lumito AB ranks worse than 99.51% on this metric.
The historical rank and industry rank for Lumito AB's OCF Margin % or its related term are showing as below:
NGM:LUMITO'
s OCF Margin % Range Over the Past 10 Years
Min: -31331.31 Med: -31331.31 Max: -31331.31
Current: -32934.62
During the past 9 years, the highest OCF Margin % of Lumito AB was -31331.31%. The lowest was -31331.31%. And the median was -31331.31%.
NGM:LUMITO's OCF Margin % is ranked worse than 99.51% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.84
vs NGM:LUMITO: -32934.62
Lumito AB OCF Margin % Related Terms
Lumito AB OCF Margin % Historical Data
* Premium members only.
The historical data trend for Lumito AB's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:LUMITO vs TMO, DHR, IDXX: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Lumito AB's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumito AB OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lumito AB's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Lumito AB's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumito AB (NGM:LUMITO) has a OCF Margin % of -8,630.77% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Lumito AB and its competitors. According to the industry distribution chart, Lumito AB ranks #202 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 99.5%.
Is Lumito AB's OCF Margin % too high?
Lumito AB's current OCF Margin % is -8,630.77%. Based on the distribution chart, Lumito AB ranks #202 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Lumito AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Lumito AB's OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lumito AB ranks #202 out of 203 companies for OCF Margin %. This places Lumito AB in the lower half of its industry. The industry median OCF Margin % is 4.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.84, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Lumito AB and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumito AB's current OCF Margin % is -8,630.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumito AB stock overvalued right now?
Lumito AB (NGM:LUMITO) has a current OCF Margin % of -8,630.77%. The current OCF Margin % is -8,630.77%. Lumito AB's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Lumito AB (NGM:LUMITO), the current OCF Margin % is -8,630.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lumito AB is a Swedish company that specializes in the medical research and development of imaging technology for use in digital pathology. It has developed the next-generation tissue analysis system, based on upconverting nanoparticles (UCNPs). Lumito SCIZYS is a cutting-edge, high-sensitivity system combining labeling and imaging technologies to locate and measure biomarkers in tissue samples. The company holds a broad patent portfolio of three patent families. Lumito's solution enables quantitative and objective assessment of tissue samples, addressing a multitude of challenges in drug development and academic research.
18GF Score
Get the complete analysis for NGM:LUMITO
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:LUMITO has been successfully added to your 
